


# Spatially Fractionated Radiation Therapy for Durable Palliation


Elizabeth Zhang-Velten, MD, PhD

Clinical Assistant Professor of Radiation Oncology

USC Norris Comprehensive Cancer Center  
at Newport Beach & Buena Park



@radiation.doc




# Objectives


- ◇ Define SFRT
- ◇ Discuss the challenges of treating bulky tumors
- ◇ Review the history of SFRT
- ◇ Case discussions
- ◇ Overview of the USC experience

# What is Spatially Fractionated Radiation Therapy?


- ◇ SFRT is a mode of external beam radiation therapy characterized by a highly non-uniform dose distribution
- ◇ It's “spatially fractionated” because the dose varies across space
- ◇ Often described as having “peak” and “valley” doses



# The challenge of bulky tumors




# The challenge of bulky tumors: volume




- Expected response probability
- Head and neck [Hjelm-Hansen et al. 1979]
- ▲ Head and neck [Van den Bogaert et al. 1995]
- ◆ Head and neck [Johnson et al. 1995a]
- ▼ T3 glottic larynx [Pameijer et al. 1997]
- Melanoma [Overgaard et al. 1986]
- ◇ Breast cancer [Arriagada et al. 1985]
- △ Cervix cancer [Mendenhall et al. 1994]
- ▽ Cervix cancer [Magee et al. 1991]

Dubben, Hans-Hermann, Howard D. Thames, and Hans-Peter Beck-Bornholdt. "Tumor volume: a basic and specific response predictor in radiotherapy." *Radiotherapy and oncology* 47.2 (1998): 167-174.

# The challenge of bulky tumors: OAR overlap



# The challenge of bulky tumors: OAR overlap



Sveistrup et al. *Radiation Oncology* 9.1 (2014): 44.

# History of Spatially Fractionated Radiation Therapy

- ◇ 1909: Kohler publishes the first description of SFRT
  - ◇ **Kilovoltage x-rays**
  - ◇ Wire-mesh placed over x-ray tube to intentionally shield the skin in an intentional pattern to allow healing
  - ◇ Administered massive doses, 10-20 times the total dose usually given at that time through a conventional open field.



Dr. Alban Köhler

# Spatially Fractionated Radiation Therapy in 1932



## THE VALUE OF A MULTI-PERFORATED SCREEN IN DEEP X-RAY THERAPY<sup>1</sup>

A PRELIMINARY REPORT ON A NEW METHOD OF DELIVERING MULTIPLE  
ERYTHEMA DOSES WITHOUT PERMANENT INJURY TO THE SKIN



By F. LIBERSON, M.D., Roentgenologist, U. S. Marine Hospitals,  
STAPLETON, ELLIS ISLAND, and NEW YORK CITY

LIBERSON: A MULTI-PERFORATED SCREEN

187



# Spatially Fractionated Radiation Therapy in 1932



Figs. 5-A to 5-F. These show the arrangements of the portals of treatment in a case of neoplasm of the left side of the chest *D*, with metastasis in the cervical spine. The tumor is plotted on a topographical cross-section of the chest. *A* shows the plotting of one of the suitable streamers of size sufficient to cover the tumor by a small margin, the streamer directed from the left axilla anterior to the right axilla posterior. *B*, directing the streamer from the left axilla posterior to the right axilla anterior. *C*, from the left back to the left front. Note that in *E* all streamers cross in the region of the tumor, but neither the entrance nor the exit rays cross at any skin surface. *F* shows the appearance of the skin two weeks after treatment with three erythema doses through the perforator.

# Spatially Fractionated Radiation Therapy in 1932

The fact that the same recommendations which I made in 1909 have also been made in December, 1932, indicates that the method has a future.

ALBAN KÖHLER

# Then in the 1950s: MVs

1056


R. F. ROBISON

*Acta Oncologica* 34 (1995)



Fig. 1. The Acme telecobalt unit.

Fig. 2. The Eldorado telecobalt unit.




Robison, Roger F. "The race for megavoltage x-rays versus telegamma." *Acta Oncologica* 34.8 (1995): 1055-1074.

# Then in the 1950s: MVs

- ◆ As a result of this technology shift, grid therapy became less utilized





**Grid for skin  
recovery**



**Inherent skin-  
sparing at MV  
energies**

But the problem remains...




1990s:



# 1990s:



**Grid for skin  
recovery**



**Grid for deeper  
normal tissue  
recovery**


# History of Spatially Fractionated Radiation Therapy

- ◇ 1909: Kohler publishes the first description of SFRT
  - ◇ **Kilovoltage x-rays**
  - ◇ Wire-mesh placed over x-ray tube to intentionally shield the skin in an intentional pattern to allow healing
  - ◇ Administered massive doses, 10-20 times the total dose usually given at that time through a conventional open field.



Dr. Alban Köhler

1990s:



Big doses in  
bulky tumors

Grid

Skin-sparing MV  
radiation on linear  
accelerator

# 1990: Grid therapy on MV linac




FIG. 1. The Jefferson "Hexaboard Array" GRID that fits into the alloy tray of the linear accelerator.

TABLE 1. Distribution of Patients

	No. of patients	Prior XRT	Concurrent XRT
Osteosarcoma	6	—	5
Liposarcoma	2	—	2
Leiomyosarcoma	1	—	—
Colorectal CA	6	4	2
Liver	3	—	2
Squamous (vagina)	1	1	1
Renal cell CA	1	—	1
Melanoma	1	—	1
Adeno CA (prostate)	1	1	—
Total	22	6	14



CA: carcinoma; XRT: radiation therapy; Adeno CA: adenocarcinoma.

TABLE 3. Response Rate as a Function of the Four Most Common Symptoms

Symptoms	Total no.	CR (%)	PR (%)	Total response	
				CR + PR	NR (%)
Pain	19	5 (26)	12 (67)	89%	2 (7)
Edema	3	—	3 (100)	100%	—
Bleeding	4	4 (100)	—	100%	—
Mass effect	5	—	4 (80)	80%	—



CR: complete response; PR: partial response; NR: no response.

# 1990: Grid therapy on MV linac




Mohiuddin, Mohammed, et al. "Palliative treatment of advanced cancer using multiple nonconfluent pencil beam radiation: a pilot study." *Cancer* 66.1 (1990): 114-118.

# 2000s: Grid using MLCs




# 2010: Grid $\rightarrow$ Lattice




Wu et al, Cureus 2010

# Spatially Fractionated Radiation Therapy (SFRT)



# How does it work?

- ◇ Bystander effect
- ◇ Vascular effects
- ◇ Immunomodulation




Tubin et al., Radiation Oncology 14.1 (2019): 21.

# How we plan SFRT at USC


- ◇ 4 cm sphere-to-sphere distance
- ◇ 1 cm sphere-to-GTV surface distance
- ◇ Homegrown software to maximum number of spheres in GTV while still meeting the above criteria

# Case 1:

- 86 yo man with metastatic castrate-resistant prostate cancer and very locally aggressive bulky primary tumor



- ◇ SFRT with 15 Gy in 1 fraction to internal spheres
- ◇ VMAT with specific intent to create high-dose hot spots distributed throughout a **bulky** tumor, while keeping the remainder of the tumor volume and tumor surface dose low





Bladder (INVADED)

Tumor


Rectum



# 9 months later...



Bladder now identifiable



Tumor decreased  
from 915 cc to 47  
cc (-95%)


Rectum decompressed (patient reported resolution of constipation)

## Case 2:


- ◇ 50 yo man with metastatic gastrointestinal stromal tumor (GIST) and symptomatic right retroperitoneal tumor conglomerate invading the psoas, causing pain
- ◇ SFRT with 66.7 Gy in 5 fractions SIB to internal spheres, 20 Gy in 5 fractions to entire tumor



3 months post-RT



6 months post-RT



# Our institutional experience

- ◇ 29 adult patients treated with SFRT since 2024
  - ◇ 17 patients (59%) received single-fraction SFRT with 3 Gy to gross tumor volume (GTV) and 15 Gy to the vertices
  - ◇ 12 patients (41%) received 5-fraction SFRT with 20 Gy to GTV and 66.7 Gy to the high-dose vertices
- ◇ 6X-FFF VMAT technique

# Patient Characteristics

- ◇ Median age 71
- ◇ Median ECOG 1
- ◇ Median of 3 prior lines of systemic therapy
- ◇ 12 patients (41%) received prior radiation to the local site
- ◇ Median GTV size **368.3 cc** (IQR 205.8 cc – 903.4 cc)
- ◇ Most patients (21, 72.4%) presented with pain

# Outcomes

- ◆ 24 of 29 patients (83%) had follow up, median 7 months.
  - Only 3 patients (12%) did not experience improvement of symptoms.
  - Of the 22 patients who had post-SFRT diagnostic imaging, objective response rate was 72.7%, with median GTV volume decrease of 54.4% at last imaging evaluation.

# Toxicities

- ◆ The most common acute toxicity was fatigue (24%).
- ◆ 13 patients (52%) had no acute toxicities.
- ◆ One grade 3+ toxicity observed as fistula between neobladder and pre-existing anorectal fistula, possibly due to either tumor progression or radiation treatment.

# Conclusion:

## SFRT is a modern solution for a modern problem

- ◆ Oncologic advances have enabled patients with metastatic disease to live longer, often after multiple lines of systemic therapy and prior radiation
- ◆ SFRT is a novel option which was well-tolerated and provided a favorable objective response rate of 72.7% in our patients with limited alternatives for palliation.
- ◆ Larger prospective studies are needed to refine patient selection and guide clinical guidelines for SFRT.

# Acknowledgements

## ◆ USC Radiation Oncology Department

### ◆ Computer Science

◆ Arjun Karnwal

### ◆ OC Radiation Therapists

◆ April Lucke RT (R)(T)

◆ Yaqueni Flamenco RT (R)(T)

◆ Jenae Shindler RT (R)(T)

◆ Anthoni Gustus RT (R)(T)

### ◆ SFRT MD Working Group

◆ Kenneth Wong, MD

◆ Jason Ye, MD

◆ May Tao, MD

◆ Hirsch Matani, MD

◆ Andrew Lim, MD

◆ Lauren Lukas, MD

◆ Joshua Schiff, MD

◆ Diane Ling, MD

### ◆ Medical Physics

◆ Arthur Olch, PhD


◆ Hualin Zhang, PhD

◆ Salim Balik, PhD

◆ Zhengzheng Xu, PhD

◆ Benjamin Ziemer, PhD

◆ Zhilei Shen, PhD



@radiation.doc